Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients (OPALESCENCE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04758780 |
|
Recruitment Status :
Recruiting
First Posted : February 17, 2021
Last Update Posted : February 21, 2023
|
Sponsor:
Institut Cancerologie de l'Ouest
Collaborators:
Telix Pharmaceutical
SIRIC ILIAD
Information provided by (Responsible Party):
Institut Cancerologie de l'Ouest
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 2024 |
| Estimated Study Completion Date : | June 2024 |